Bronchodilator
Pregnancy: B — minimal systemic absorption; inhaled route considered safe
Ipratropium Bromide
Brand names: Atrovent, Rinatec
Adult dose
Dose: Inhaled MDI: 20–40mcg (1–2 puffs) TDS–QDS. Nebulised: 250–500mcg
Route: Inhaled / Nebulised
Frequency: Three to four times daily; nebulised every 4–6h in acute exacerbation
Max: 2mg/day nebulised
Acute severe asthma (with salbutamol): 500mcg nebulised. COPD exacerbation: 250–500mcg nebulised every 4–6h. Added to salbutamol in acute asthma for additive bronchodilation.
Paediatric dose
Route: Nebulised (acute asthma) / Inhaled MDI + spacer (chronic)
Frequency: Every 20–30 min in acute severe asthma (combined with salbutamol); every 4–6 h thereafter
Max: 500 micrograms per nebulised dose
Concentration: 0.25 mg/ml
Age bands
- 1–60m: Nebulised 125 micrograms every 20–30 min
- 60–144m: Nebulised 250 micrograms every 20–30 min
- 144–216m: Nebulised 500 micrograms every 20–30 min
BNFc / BTS-SIGN paediatric asthma — fixed dose by age, not weight: nebulised 125 micrograms (child 1 month–5 years) or 250 micrograms (child 6–11 years) or 500 micrograms (child 12+ years), every 20–30 min in acute severe asthma combined with salbutamol; thereafter every 4–6 h.
Clinical pearls
- In acute severe asthma: adding ipratropium 500mcg to salbutamol nebulisers significantly reduces hospitalisation rate (Cochrane review).
- In COPD exacerbations: add ipratropium to salbutamol for acute bronchodilation. Switch to long-acting anticholinergic (tiotropium) for maintenance.
- Use a mouthpiece (not face mask) for nebulisation to avoid ocular exposure and risk of acute angle-closure glaucoma.
- Short-acting (duration 4–6h). Tiotropium is the long-acting equivalent for COPD maintenance.
Contraindications
- Hypersensitivity to atropine or ipratropium
- Acute angle-closure glaucoma (avoid nebulisation near eyes)
- Bladder neck obstruction / BPH (relative)
Side effects
- Dry mouth (most common)
- Paradoxical bronchospasm (rare)
- Acute angle-closure glaucoma if nebulised mist contacts eyes
- Urinary retention (especially elderly males with BPH)
- Tachycardia (less than salbutamol)
Interactions
- Other anticholinergic drugs: additive anticholinergic effects
- Tiotropium: do not use together — additive anticholinergic toxicity
Monitoring
- FEV₁ / peak flow
- HR
- symptoms of urinary retention
Reference: BNFc; BTS/SIGN Asthma 2023; GOLD COPD Report 2024; NICE BNF 84. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
- Community-Acquired Pneumonia (CURB-65) · BTS 2009 / NICE NG138
- Acute Pulmonary Embolism · BTS 2003 / ESC 2019
- Pleural Effusion Assessment · BTS 2010